Publications by authors named "Lali Kilasonia"
Article Synopsis
- The study investigated the efficacy and safety of the biosimilar BAT1806/BIIB800 compared to the reference drug tocilizumab (TCZ) in patients with moderate-to-severe rheumatoid arthritis over a treatment period of 24-48 weeks.
- Results showed that the effectiveness of both treatments was similar, with high response rates (ACR20), along with comparable safety and immunogenicity profiles across treatment groups.
- Overall, the study concluded that BAT1806/BIIB800 has similar therapeutic outcomes to TCZ, supporting its use as a treatment option for rheumatoid arthritis patients.
Background: Biosimilars provide an opportunity to address unmet medical need by expanding access to biological treatments. This study aimed to show equivalent efficacy, and comparable safety, immunogenicity, and pharmacokinetic profiles of a proposed tocilizumab biosimilar BAT1806/BIIB800, to reference tocilizumab, in participants with rheumatoid arthritis with an inadequate response to methotrexate.
Methods: This phase 3, multicentre, randomised, double-blind, active-controlled, equivalence study comprised a 24-week initial treatment period (results reported here) and a 24-week secondary treatment period.